Net sales down 10.0% to €911.9 million, driven by lower volumes for Sanofi and the suspension of production at Brindisi, only ...

Major pharmaceutical products and medicines have jumped in prices despite and executive order by President Bola Tinubu, ...

Management provided guidance of $115 million in U.S. BRIUMVI net revenue for Q1 2025 and reiterated the full-year 2025 target of $525 million. January and February 2025 were noted as the highest ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

CLEVELAND, Ohio — Eggs are disappearing from store shelves due to shortages caused by the avian flu outbreak, but never fear — the eggs used to make the flu vaccine are safe.

Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

Q4 2024 Management View CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, ...

With a market valuation of Rs 11,574.76 Cr, Sanofi Indias shares ended Fridays trading session on the BSE 0.58% higher at Rs ...

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...